<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01141153</url>
  </required_header>
  <id_info>
    <org_study_id>MUSICA-2</org_study_id>
    <secondary_id>2009-017256-27</secondary_id>
    <nct_id>NCT01141153</nct_id>
  </id_info>
  <brief_title>Anticoagulation in Stent Intervention</brief_title>
  <acronym>MUSICA-2</acronym>
  <official_title>Test of Efficacy and Safety of the Dual Antiplatelet Therapy Compared to the Combination of Oral Anticoagulant Therapy + Dual Antiplatelet Therapy in Patients With Atrial Fibrillation With Low-moderate Risk Submitted to Coronary Stent Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective:

      The main objective is to evaluate the pattern of dual antiplatelet therapy (aspirin, 300 mg /
      day + clopidogrel 75 mg / day) compared to the use of the triple regimen (Acenocoumarol as
      control + acetylsalicylic acid 100 mg / day + Clopidogrel 75 mg / day) in patients with
      atrial fibrillation, low-moderate risk of stroke (CHADS ≤ 2) who are undergoing PCI-S.

      Design:

      Randomized, parallel, with two arms, blind evaluation by third parties.

      Patients:

      304 patients undergoing PCI-S with atrial fibrillation, low-moderate risk of stroke (CHADS ≤
      2), which requires prevention of thrombosis
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A composite of stroke, myocardial infarction, systemic thromboembolism, stent thrombosis and death</measure>
    <time_frame>until 12 months</time_frame>
    <description>Incidence of the composite major events (stroke, myocardial infarction, systemic thromboembolism, stent thrombosis and death) until 12 months after the initial treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of major and minor bleeding</measure>
    <time_frame>until 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>until 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">304</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Oral anticoagulation plus dual antiplatelet therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dual antiplatelet therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic Acid + clopidogrel + acenocoumarol</intervention_name>
    <description>Acetylsalicylic Acid 100 mg daily + Clopidogrel 75 mg daily + Acenocoumarol dosage with INR monitoring
Treatment : 6 weeks for bare metal stent and 12 months for drug elution stent</description>
    <arm_group_label>Oral anticoagulation plus dual antiplatelet therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic Acid + clopidogrel</intervention_name>
    <description>Salicylic Acid, 300 mg daily + Clopidogrel 75 mg daily
Treatment : 6 weeks for bare metal stent and 12 months for drug elution stent.</description>
    <arm_group_label>Dual antiplatelet therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of both sexes older than 18 years.

          -  Patients with permanent atrial fibrillation, persistent or paroxysmal (at least one
             episode), documented electrocardiographically and receiving oral anticoagulation.
             Patients with acute coronary syndrome or stable angina who are undergoing PCI-S.

          -  Patients who have previously given their informed consent to participation in the
             study.

        Exclusion Criteria:

          -  Patients who can not be followed by the research team during the 12 months provided
             for monitoring.

          -  Patients with renal failure or serum creatinine above 2 mg • dL-1, neurological
             deficits, active ulcer or epigastric pain.

          -  Patients who continue regular treatment with NSAIDs or other analgesics or
             corticosteroids.

          -  Patients undergoing reoperation.

          -  Patients who during the study period, should receive, according to medical criteria,
             other adjuvant drug treatment than that specified in this protocol.

          -  Pregnant women.

          -  Use of investigational agents or not registered within 30 days of entry into the
             study.

          -  Patients with a history of allergy to study drugs or excipients.

          -  Patients with severe valve disease.

          -  Patients with CHADS&gt; 2.

          -  Patients who can not use the study drug orally.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonia Sambola, MD Ph</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>David García -Dorado, MD Ph</last_name>
    <role>Study Director</role>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporación Sanitaria Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta del Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr.Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2010</study_first_submitted>
  <study_first_submitted_qc>June 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2010</study_first_posted>
  <last_update_submitted>February 23, 2015</last_update_submitted>
  <last_update_submitted_qc>February 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>Coronary Stent implantation</keyword>
  <keyword>Low-moderate risk of stroke</keyword>
  <keyword>dual antiplatelet therapy</keyword>
  <keyword>anticoagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Acenocoumarol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

